Browse VCX

Summary
SymbolVCX
Namevariable charge, X-linked
Aliases VCX1; VCX10R; VCX-10r; VCX-B1; variable charge, X chromosome; VCX-10r-B1; VCXB1; variable charge protein on ......
Chromosomal LocationXp22.31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location -
Domain PF15231 Variable charge X/Y family
Function

May mediate a process in spermatogenesis or may play a role in sex ratio distortion.

> Gene Ontology
 
Biological Process GO:0007283 spermatogenesis
GO:0022613 ribonucleoprotein complex biogenesis
GO:0022618 ribonucleoprotein complex assembly
GO:0042254 ribosome biogenesis
GO:0042255 ribosome assembly
GO:0048232 male gamete generation
GO:0071826 ribonucleoprotein complex subunit organization
Molecular Function GO:0003682 chromatin binding
Cellular Component -
> KEGG and Reactome Pathway
 
KEGG -
Reactome -
Summary
SymbolVCX
Namevariable charge, X-linked
Aliases VCX1; VCX10R; VCX-10r; VCX-B1; variable charge, X chromosome; VCX-10r-B1; VCXB1; variable charge protein on ......
Chromosomal LocationXp22.31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between VCX and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 
  Literatures describing the relation between VCX and anti-tumor immunity in human cancer.
PMID Cancer type Relation to immunity Evidence sentences
24970476lung adenocarcinomasPromote immunityAmong CT antigens with concordant mRNA and protein expression levels, four CT antigens, XAGE1, VCX, IL13RA2, and SYCE1, were expressed, alone or in combination, in about 80% of lung adenocarcinoma tumors.
Summary
SymbolVCX
Namevariable charge, X-linked
Aliases VCX1; VCX10R; VCX-10r; VCX-B1; variable charge, X chromosome; VCX-10r-B1; VCXB1; variable charge protein on ......
Chromosomal LocationXp22.31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of VCX in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolVCX
Namevariable charge, X-linked
Aliases VCX1; VCX10R; VCX-10r; VCX-B1; variable charge, X chromosome; VCX-10r-B1; VCXB1; variable charge protein on ......
Chromosomal LocationXp22.31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of VCX in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14120.8830.183
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)651.3660.201
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)870.5350.561
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9161.0790.473
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590.6550.756
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 471.610.5
729033130MelanomaallAnti-PD-1 (nivolumab) 2623-1.70.0971
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 1511-1.0790.509
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1112-2.1690.262
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 4801
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 2801
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 682300.3680.374
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of VCX in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27733.703.70.27
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27593.703.70.314
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21179.55.93.61
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)86250250.473
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)131109.1-9.10.458
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38272.63.7-1.11
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22134.57.7-3.21
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolVCX
Namevariable charge, X-linked
Aliases VCX1; VCX10R; VCX-10r; VCX-B1; variable charge, X chromosome; VCX-10r-B1; VCXB1; variable charge protein on ......
Chromosomal LocationXp22.31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of VCX. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolVCX
Namevariable charge, X-linked
Aliases VCX1; VCX10R; VCX-10r; VCX-B1; variable charge, X chromosome; VCX-10r-B1; VCXB1; variable charge protein on ......
Chromosomal LocationXp22.31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of VCX. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by VCX.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolVCX
Namevariable charge, X-linked
Aliases VCX1; VCX10R; VCX-10r; VCX-B1; variable charge, X chromosome; VCX-10r-B1; VCXB1; variable charge protein on ......
Chromosomal LocationXp22.31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of VCX. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolVCX
Namevariable charge, X-linked
Aliases VCX1; VCX10R; VCX-10r; VCX-B1; variable charge, X chromosome; VCX-10r-B1; VCXB1; variable charge protein on ......
Chromosomal LocationXp22.31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of VCX expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolVCX
Namevariable charge, X-linked
Aliases VCX1; VCX10R; VCX-10r; VCX-B1; variable charge, X chromosome; VCX-10r-B1; VCXB1; variable charge protein on ......
Chromosomal LocationXp22.31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between VCX and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolVCX
Namevariable charge, X-linked
Aliases VCX1; VCX10R; VCX-10r; VCX-B1; variable charge, X chromosome; VCX-10r-B1; VCXB1; variable charge protein on ......
Chromosomal LocationXp22.31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting VCX collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.